mug113 Antibody

What is mug113 Antibody and what target does it recognize?

Mug113 antibody (product code CSB-PA608752XA01SXV) is a research-grade antibody that recognizes the mug113 protein (Q10180) in Schizosaccharomyces pombe (fission yeast) . Unlike some antibodies that target conserved epitopes across multiple species, mug113 antibody appears to be species-specific. This specificity is important when designing experiments, as antibodies that cross-react with similar proteins in other species can confound research findings, similar to how the GB113 monoclonal antibody demonstrates high specificity for its target without cross-reactivity to similar alpha/beta heterodimers .

What are the typical formats and storage conditions for optimal mug113 antibody performance?

While the search results don't provide specific information about mug113 antibody storage, research-grade antibodies typically require storage at -20°C for long-term stability or at 4°C for short-term use. Proper handling is critical as antibody function depends on maintaining protein structure. Researchers should avoid repeated freeze-thaw cycles, which can lead to denaturation and loss of binding activity, similar to other monoclonal antibodies used in research settings . When planning long-term experiments, consider aliquoting the antibody into single-use volumes to preserve activity throughout the research timeline.

How does the molecular structure of mug113 antibody influence its binding properties?

The molecular structure of mug113 antibody, like other research antibodies, contains variable regions that determine its binding specificity. The antibody's affinity for its target is influenced by complementarity-determining regions (CDRs) that form the antigen-binding site. Similar to how MW11-h317 shows high affinity for PD-1 through specific structural interactions , mug113 antibody likely contains paratopes specifically evolved to recognize epitopes on the mug113 protein. Understanding this structure-function relationship is essential when interpreting binding data, especially when comparing results across different experimental systems or antibody lots.

What are the validated applications for mug113 antibody in fission yeast research?

Based on antibody application patterns in similar research systems, mug113 antibody may be suitable for techniques including Western blotting, immunoprecipitation, and immunofluorescence in Schizosaccharomyces pombe research . When designing experiments, researchers should consider validation across multiple applications since antibody performance can vary significantly between techniques. For reliable results, preliminary validation experiments should be conducted in your specific experimental system before proceeding with larger studies, as third-party testing has shown that many commercial antibodies fail to perform consistently across all applications they are advertised for .

How should researchers design proper controls when using mug113 antibody in immunofluorescence studies?

For robust immunofluorescence experiments with mug113 antibody, researchers should implement a comprehensive control system:

Rigorous controls are essential as third-party testing has revealed that only about one-third of commercially available antibodies successfully recognize their targets in the applications recommended by manufacturers . Additionally, creating CRISPR-based knockout controls can provide definitive evidence of antibody specificity, similar to the validation approaches described for neuroscience-related antibodies .

What are the optimal dilution ranges for mug113 antibody across different experimental techniques?

While specific dilution recommendations for mug113 antibody are not provided in the search results, researchers should perform titration experiments to determine optimal concentrations for each application. Typically, starting dilution ranges might include:

• Western blotting: 1:500-1:5000

• Immunofluorescence: 1:100-1:500

• Immunoprecipitation: 1:50-1:200

These ranges should be experimentally determined for each new lot of antibody, as binding efficiency can vary between batches. Similar to antibody validation approaches in other systems, researchers should test multiple dilutions and incubation conditions to identify parameters that maximize specific signal while minimizing background . Documentation of optimization experiments enhances reproducibility and supports reliable interpretation of results across different experimental conditions.

What strategies should researchers employ to verify the specificity of mug113 antibody?

Comprehensive validation of mug113 antibody specificity should include multiple orthogonal approaches:

• Genetic validation: Test antibody reactivity in wild-type vs. mug113 knockout strains to confirm target specificity

• Recombinant protein controls: Express and purify recombinant mug113 for positive control experiments

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to block specific binding

• Cross-species testing: Assess reactivity in organisms with and without mug113 homologs

• Orthogonal detection methods: Compare antibody-based detection with tagged protein expression or mass spectrometry

These approaches align with findings that independent third-party validation is essential for identifying high-quality antibodies . Studies have shown that commercially available antibodies often fail specificity tests, with only around one-third of polyclonal and monoclonal antibodies recognizing their targets in applications they were recommended for . Establishing rigorous validation protocols is therefore critical before using mug113 antibody in definitive experiments.

How can researchers determine if their mug113 antibody detects post-translational modifications?

To assess whether mug113 antibody recognizes specific post-translational modifications (PTMs), researchers should:

• Compare reactivity between native and recombinant proteins (which may lack PTMs)

• Treat samples with enzymes that remove specific modifications (phosphatases, deglycosylases)

• Generate modified and unmodified peptides for competitive binding assays

• Use mass spectrometry to correlate antibody binding with specific modification states

This approach is supported by findings that antibody recognition can be significantly affected by target protein modifications, as demonstrated in studies of glycosylation-dependent antibody binding to PD-1 . Understanding whether mug113 antibody detects PTMs is crucial for accurate interpretation of experimental results, particularly when studying dynamic cellular processes where protein modifications may change in response to experimental conditions.

How can mug113 antibody be used in multiplexed imaging approaches for studying protein interactions?

For advanced multiplexed imaging studies, researchers can integrate mug113 antibody into protocols similar to IBEX multiplex tissue imaging systems referenced in antibody repositories . Implementation requires:

• Compatibility testing with fixation protocols that preserve epitope accessibility

• Optimization of antibody stripping/elution conditions between imaging rounds

• Selection of compatible fluorophores with minimal spectral overlap

• Development of computational pipelines for image registration and analysis

• Validation of staining patterns against orthogonal methods

When designing multiplexed experiments, researchers should consider that antibody performance can vary dramatically under different fixation and permeabilization conditions. Sequential staining approaches may be necessary if antibodies from the same species are used for multiple targets. Similar to established multiplexed imaging systems, researchers should validate that mug113 epitope recognition is not compromised by preceding imaging cycles .

What considerations are important when using mug113 antibody for quantitative proteomic analysis?

When incorporating mug113 antibody into quantitative proteomics workflows:

• Determine the linear dynamic range of detection for accurate quantification

• Assess pull-down efficiency through recovery of spiked-in standards

• Evaluate potential impacts of protein-protein interactions on epitope accessibility

• Optimize elution conditions to minimize co-immunoprecipitation of interacting partners

• Compare results with orthogonal quantification methods (e.g., MRM-MS)

Quantitative applications require particularly rigorous validation, as studies have shown significant variability in antibody performance across different experimental contexts . When using mug113 antibody for protein quantification, researchers should establish standard curves with recombinant standards and implement appropriate normalization strategies to account for technical variability between experiments, similar to approaches used in other antibody-based quantitative analyses.

How does clone selection influence the performance of mug113 monoclonal antibodies in different applications?

If multiple monoclonal clones of mug113 antibody are available, their performance may vary substantially across applications due to recognition of different epitopes. Similar to findings with other antibodies, researchers should evaluate:

• Epitope accessibility under various sample preparation conditions

• Differential recognition of protein conformations (native vs. denatured)

• Sensitivity to specific buffer components or detergents

• Clone-specific cross-reactivity profiles

• Variation in affinity and specificity across experimental conditions

This approach is supported by research showing that monoclonal antibodies recognizing different epitopes on the same protein can perform drastically differently across applications . For critical experiments, testing multiple clones may be necessary to identify the optimal antibody for each specific application, as epitope accessibility can vary significantly between techniques like Western blotting (denatured proteins) and immunoprecipitation (native conformation) .

What are the common causes of false positive signals when using mug113 antibody, and how can they be mitigated?

False positive signals with mug113 antibody may arise from multiple sources:

Third-party validation studies have revealed that many antibodies bind to additional, non-target proteins or fail to recognize their intended targets altogether . Particularly concerning is research showing that even widely cited antibodies may demonstrate poor specificity, potentially contributing to irreproducible results in published literature . Implementing comprehensive controls for each experiment is therefore essential for distinguishing true signals from artifacts.

How should researchers address batch-to-batch variability in mug113 antibody performance?

To manage batch-to-batch variability:

• Maintain reference samples with established staining patterns/intensities

• Perform side-by-side validation when switching to new antibody lots

• Document lot-specific optimal dilutions and conditions

• Consider pooling antibody aliquots for long-term studies

• Implement normalization strategies for quantitative applications

Studies have highlighted significant variability between antibody batches, even from the same manufacturer . This variability underscores the importance of batch-specific validation, particularly for quantitative studies where consistent performance is essential. For critical experiments, researchers might consider securing sufficient antibody from a single lot to complete the entire study, or alternatively, using recombinant antibodies which demonstrate greater lot-to-lot consistency .

What advanced fixation and epitope retrieval methods can enhance mug113 antibody performance in challenging samples?

For optimal epitope detection in difficult samples:

• Compare cross-linking fixatives (formaldehyde) vs. precipitating fixatives (alcohols)

• Test graded fixation series to identify optimal fixation duration

• Evaluate heat-induced vs. enzymatic epitope retrieval methods

• Assess the impact of different detergents on membrane permeabilization

• Consider alternative sample preparation approaches (frozen vs. paraffin-embedded)

Different epitopes show variable sensitivity to fixation and retrieval conditions. For example, some antibodies perform optimally in formalin-fixed, paraffin-embedded tissues after specific antigen retrieval protocols, as demonstrated with smooth muscle Myosin heavy chain 11 antibody . Systematic optimization of these parameters for mug113 antibody can significantly enhance signal intensity and specificity, particularly in challenging samples or when detecting low-abundance targets.